Perplexity AI Predicts Whether Moderna Stock Can Make Investors Rich in 2026

A single trial readout just doubled a company’s market value in one session. Perplexity AI predicts the rerating continues, and the price prediction places Moderna at $180 to $240 by the end of 2026 with a $210 bullish base case.

The catalyst is Intismeran, the personalized mRNA cancer vaccine. Perplexity calls it the dominant valuation driver going forward. The Phase 3 INTerpath-001 melanoma trial met both primary endpoints. Recurrence-free survival and distant-metastasis-free survival both cleared alongside Keytruda.

That is the first late-stage validation of Moderna’s oncology platform. Perplexity frames it as potentially supporting a major melanoma-market opportunity.

Two near-term items support the case. FDA approval of mFLUSIVA adds a commercial product with revenue before oncology arrives. Even more, its reduced 2026 cost guidance improves cash-burn expectations. Together, they buy time for the oncology thesis to develop.

The risks are all data-dependent. Disappointing hazard ratios sit at the top of the list. Overall-survival data, pricing, and approval timing follow. Any of those could drive the stock toward $125 to $150.

… Continue reading the full article at the original source below.